The safety of SQ HDM sublingual immunotherapy tablets in patients with HDM-induced allergic rhinitis in Japan (interim analysis of post-marketing surveillance from 2016 to 2019)

[PE23-3] The safety of SQ HDM sublingual immunotherapy tablets in patients with HDM-induced allergic rhinitis in Japan (interim analysis of post-marketing surveillance from 2016 to 2019)

Shiori Saito, Yuriko Maekawa, Remi Hashimoto, Keiichi Taniguchi, Chiyoko Kunishima, Noriaki Nishino (Torii Pharmaceutical Co., Ltd., Japan)

The password to see abstracts was announced to registrants by email.